TRex Bio, Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
TRexBio, a clinical-stage biotech focused on tissue Treg immunotherapy, completed a $133.5M IPO in October 2026 (9.5M shares at $14/share; net proceeds ~$119M), extending cash runway to H2 2029. Lead candidate TRB-061 showed positive Phase 1a proof-of-mechanism in healthy volunteers with no serious adverse events; Phase 1b atopic dermatitis data expected mid-2027. Secondary candidate TRB-071 advancing toward Phase 1 initiation in H1 2027.
Why this rating
IPO capital materially extends runway; clinical data supports mechanism. Pre-IPO cash $78.2M plus $119M net proceeds = substantial resource extension for early-stage biotech with modest burn (~$13-15M/quarter). Significant but pre-commercial; upside dependent on Phase 1b outcomes.
Tradability signal
NO TRADE
No trade: positive news with only +2.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $13.67 ▲ 0.00% | at our read · unknown $13.67 | +10 min · unknown $13.55 ▼ 0.88% | +30 min · unknown $13.49 ▼ 1.29% | +1 hr · unknown $12.75 ▼ 6.73% | +4 hrs · unknown $12.36 ▼ 9.58% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.